Helix BioPharma Corp. has announced the addition of two seasoned executives to its leadership team, a move designed to propel the company's oncology research and communication efforts. Veronika Kandziora has been appointed as Chief Operating Officer, bringing with her over two decades of leadership experience in the biopharma, financial, and consulting sectors. Dr. Jessica Kourniaktis joins as Director of Communications, offering a decade of expertise in life sciences communication. These appointments underscore Helix BioPharma's dedication to advancing its mission of creating innovative treatments for challenging cancers.
Kandziora's extensive background includes serving as Corporate Secretary and strategic consultant to Helix, equipping her with a deep understanding of the company's operations and strategic goals. Her international finance and compliance experience, coupled with her training in regulatory and governance environments, positions her to enhance the company's operational and strategic alignment. Dr. Kourniaktis, with her unique blend of academic research and strategic communications experience, including founding a boutique consultancy and serving in executive roles at biopharma startups, is set to refine the company's communication strategies. Her approach, characterized by analytical depth and compelling storytelling, aims to clearly articulate the vision behind Helix BioPharma's scientific endeavors.
CEO Thomas Mehrling highlighted the strategic significance of these appointments, noting that Kandziora's leadership and Kourniaktis's strategic communications skills are pivotal for the company's progress in oncology research. Helix BioPharma's focus on developing treatments for hard-to-treat cancers is supported by its proprietary technology platform targeting CEACAM6-expressing solid tumors. The company's lead candidate, Tumour Defence Breaker™ L-DOS47, is a clinical-stage antibody-enzyme conjugate aimed at neutralizing tumor microenvironments and boosting anti-cancer immunity.
These leadership enhancements reflect Helix BioPharma's strategic initiative to bolster its operational capabilities and public engagement in the competitive oncological drug development arena. By integrating Kandziora's organizational leadership and Kourniaktis's communications expertise, the company is poised to accelerate its research and more effectively share its innovative approaches to cancer treatment with the broader community.
